Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inflammatory markers and reliever therapy use in mild to moderate asthma
2022-002677-29Phase 2Terminated
- Sponsor
- Azienda Ospedaliero-Universitaria di Ferrara
- Start
- Sep 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of budesonide, fluticasone propionate, beclomethasone and salbutamol in asthma (2 arms), sponsored by Azienda Ospedaliero-Universitaria di Ferrara. Primary endpoint: Airway inflammation characteristics and variation at symptom onset requiring reliever therapy. Started Sep 2022; status: terminated.
02
Drugs
budesonidefluticasone propionatebeclomethasonesalbutamol
03
Conditions
asthma
Beyond the preview
Go deeper on 2022-002677-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002677-29.